Sibutramine is a medication that is often used orally to treat obesity (marketed under the names Meridia in the US and Reductil in Europe and other countries). It is classed as a Schedule IV prohibited drug in the United States because it is an amphetamine-related centrally acting stimulant. Due to worries that the medication raises the risk of heart attack and stroke in people with a history of heart disease, sibutramine was taken off the market in Canada and the United States in October 2010. To overcome the associated problem, a strategy was developed where selective modification of this drug was performed by chemically reacting with a substrate (4-aminophenol) to form a new derivative [4-((4-(1-(1-(dimethylamino)-3-methylbutyl)cyclobutyl)phenyl)amino)phenol]. This novel derivative was comprehensively characterized by sophisticated analytical instruments such as FTIR, __ampersandsignsup1;H-NMR, 13C-NMR, and Mass spectroscopic spectroscopy.